Cargando…

How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial

Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment in patients with preserved LV function has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonarjee, Vernon VS, Dickstein, Kenneth
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59642/
https://www.ncbi.nlm.nih.gov/pubmed/11806788
http://dx.doi.org/10.1186/cvm-2-4-151
_version_ 1782120092196143104
author Bonarjee, Vernon VS
Dickstein, Kenneth
author_facet Bonarjee, Vernon VS
Dickstein, Kenneth
author_sort Bonarjee, Vernon VS
collection PubMed
description Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment in patients with preserved LV function has not been known. The results from the Heart Outcome Prevention Evaluation trial have indicated that long-term treatment with ramipril leads to a significant reduction in cardiovascular events in patients with atherosclerotic disease, including those with prior myocardial infarction and preserved LV function. These results suggest that long-term angiotensin-converting enzyme inhibition should also be considered in post-infarction patients with normal cardiac function.
format Text
id pubmed-59642
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-596422001-11-06 How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial Bonarjee, Vernon VS Dickstein, Kenneth Curr Control Trials Cardiovasc Med Commentary Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment in patients with preserved LV function has not been known. The results from the Heart Outcome Prevention Evaluation trial have indicated that long-term treatment with ramipril leads to a significant reduction in cardiovascular events in patients with atherosclerotic disease, including those with prior myocardial infarction and preserved LV function. These results suggest that long-term angiotensin-converting enzyme inhibition should also be considered in post-infarction patients with normal cardiac function. BioMed Central 2001 2001-06-26 /pmc/articles/PMC59642/ /pubmed/11806788 http://dx.doi.org/10.1186/cvm-2-4-151 Text en Copyright © 2001 BioMed Central Ltd
spellingShingle Commentary
Bonarjee, Vernon VS
Dickstein, Kenneth
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
title How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
title_full How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
title_fullStr How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
title_full_unstemmed How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
title_short How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
title_sort how long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the hope trial
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59642/
https://www.ncbi.nlm.nih.gov/pubmed/11806788
http://dx.doi.org/10.1186/cvm-2-4-151
work_keys_str_mv AT bonarjeevernonvs howlongshouldangiotensinconvertingenzymeinhibitorsbegiventopatientsfollowingmyocardialinfarctionimplicationsofthehopetrial
AT dicksteinkenneth howlongshouldangiotensinconvertingenzymeinhibitorsbegiventopatientsfollowingmyocardialinfarctionimplicationsofthehopetrial